IL155278A0 - Pyridinone derivatives for treatment of atherosclerosis - Google Patents
Pyridinone derivatives for treatment of atherosclerosisInfo
- Publication number
- IL155278A0 IL155278A0 IL15527801A IL15527801A IL155278A0 IL 155278 A0 IL155278 A0 IL 155278A0 IL 15527801 A IL15527801 A IL 15527801A IL 15527801 A IL15527801 A IL 15527801A IL 155278 A0 IL155278 A0 IL 155278A0
- Authority
- IL
- Israel
- Prior art keywords
- atherosclerosis
- treatment
- pyridinone derivatives
- pyridinone
- derivatives
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 150000005299 pyridinones Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Structural Engineering (AREA)
- Rheumatology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0024808.8A GB0024808D0 (en) | 2000-10-10 | 2000-10-10 | Novel compounds |
| PCT/EP2001/011610 WO2002030904A1 (fr) | 2000-10-10 | 2001-10-05 | Derives pyridinone permettant de traiter l'atherosclerose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL155278A0 true IL155278A0 (en) | 2003-11-23 |
Family
ID=9901006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15527801A IL155278A0 (en) | 2000-10-10 | 2001-10-05 | Pyridinone derivatives for treatment of atherosclerosis |
| IL155278A IL155278A (en) | 2000-10-10 | 2003-04-08 | Compressed Pyridine-4-On and Pyridine-4-On Derivatives |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL155278A IL155278A (en) | 2000-10-10 | 2003-04-08 | Compressed Pyridine-4-On and Pyridine-4-On Derivatives |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20040063753A1 (fr) |
| EP (2) | EP1326841B1 (fr) |
| JP (1) | JP4212354B2 (fr) |
| KR (1) | KR100824134B1 (fr) |
| CN (2) | CN1280275C (fr) |
| AR (1) | AR035349A1 (fr) |
| AT (1) | ATE538096T1 (fr) |
| AU (2) | AU1052402A (fr) |
| BR (1) | BRPI0114576B1 (fr) |
| CA (1) | CA2425268C (fr) |
| CY (2) | CY1112442T1 (fr) |
| CZ (1) | CZ304558B6 (fr) |
| DK (2) | DK1326841T3 (fr) |
| ES (2) | ES2399325T3 (fr) |
| GB (1) | GB0024808D0 (fr) |
| GC (1) | GC0000307A (fr) |
| HK (2) | HK1144941A1 (fr) |
| HU (1) | HU230767B1 (fr) |
| IL (2) | IL155278A0 (fr) |
| MX (1) | MXPA03003176A (fr) |
| MY (1) | MY135766A (fr) |
| NO (1) | NO325107B1 (fr) |
| NZ (1) | NZ525225A (fr) |
| PL (1) | PL207560B1 (fr) |
| PT (2) | PT1326841E (fr) |
| SI (2) | SI1326841T1 (fr) |
| TW (1) | TWI293293B (fr) |
| WO (1) | WO2002030904A1 (fr) |
| ZA (1) | ZA200302785B (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL209824B1 (pl) * | 2000-02-16 | 2011-10-31 | Smithkline Beecham Plc | 1-(N-2-(dietyloamino)etylo)-N-(4-(4-trifluorometylo-fenylo)benzylo)aminokarbonylometylo)-2-(4-fluorobenzylo)tio-5,6-trimetylenopirymidyn-4-on, jego zastosowania i zawierająca go farmaceutyczna kompozycja |
| GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| US7741020B2 (en) | 2004-04-16 | 2010-06-22 | Glaxo Group Limited | Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity |
| US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| KR101563753B1 (ko) * | 2007-05-11 | 2015-10-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 피부 궤양의 치료 방법 |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| KR101461659B1 (ko) | 2007-05-11 | 2014-11-17 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
| US9512104B2 (en) * | 2009-07-28 | 2016-12-06 | Auspex Pharmaceuticals, Inc. | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| US8575348B2 (en) | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| EP2490693A4 (fr) * | 2009-10-19 | 2013-02-27 | Merck Sharp & Dohme | Inhibiteurs de pyrazolo[3,4-b]pyridin-4-one kinase |
| AU2011268127B2 (en) | 2010-06-18 | 2016-01-14 | Whitehead Institute For Biomedical Research | PLA2G16 as a target for antiviral compounds |
| US8859573B2 (en) * | 2010-12-06 | 2014-10-14 | Glaxo Group Limited | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
| SG190830A1 (en) | 2010-12-06 | 2013-07-31 | Glaxo Group Ltd | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
| WO2012080497A2 (fr) | 2010-12-17 | 2012-06-21 | Glaxo Group Limited | Procédés de traitement et de prévention de maladies oculaires |
| WO2013000108A1 (fr) * | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | Composés hétérocycliques azoles, procédés de préparation, compositions pharmaceutiques et leurs utilisations |
| CA2843102A1 (fr) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | Composes pyrimidones bicycliques |
| AU2012289492B2 (en) | 2011-07-27 | 2016-02-04 | Glaxo Group Limited | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors |
| KR20190075172A (ko) | 2011-09-01 | 2019-06-28 | 글락소 그룹 리미티드 | 신규한 결정 형태 |
| JP2016505053A (ja) | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物 |
| AU2014210259B2 (en) | 2013-01-25 | 2016-11-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| JP6306053B2 (ja) | 2013-01-25 | 2018-04-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | ２，３−ジヒドロイミダゾール［１，２−ｃ］ピリミジン−５（１Ｈ）−オンに基づくリポタンパク質関連ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）阻害剤 |
| EP2764866A1 (fr) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibiteurs de l'enzyme activant nedd8 |
| US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| WO2016012917A1 (fr) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2 |
| WO2016012916A1 (fr) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2 |
| CN104840963B (zh) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 |
| US10464896B2 (en) | 2015-06-11 | 2019-11-05 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
| CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| PE20230092A1 (es) | 2019-11-09 | 2023-01-16 | Shanghai Simr Biotechnology Co Ltd | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceuticas y uso del mismo |
| CN112510260B (zh) * | 2020-11-27 | 2022-11-04 | 珠海市赛纬电子材料股份有限公司 | 电解液添加剂、非水电解液和锂离子电池 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5769527A (en) | 1986-07-17 | 1998-06-23 | Vari-Lite, Inc. | Computer controlled lighting system with distributed control resources |
| US5585246A (en) | 1993-02-17 | 1996-12-17 | Biometric Imaging, Inc. | Method for preparing a sample in a scan capillary for immunofluorescent interrogation |
| DE69423436T2 (de) | 1993-06-25 | 2000-09-07 | Smithkline Beecham P.L.C., Brentford | An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie |
| US5641669A (en) | 1993-10-06 | 1997-06-24 | Icos Corporation | Platelet-activating factor acetylhydrolase |
| GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| NZ298416A (en) | 1994-12-22 | 1999-03-29 | Smithkline Beecham Plc | Substituted azetidin-2-one derivatives and medicaments thereof |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| CZ422197A3 (cs) | 1995-07-01 | 1998-06-17 | Smithkline Beecham Plc | Azetidinonové deriváty, způsob jejich přípravy, meziprodukty tohoto postupu, farmaceutický prostředek obsahující tyto sloučeniny a použití těchto sloučenin jako léčiv |
| FR2743912B1 (fr) | 1996-01-24 | 1998-04-10 | Matra Communication | Circuit de resolution d'equation-cle et decodeur reed-solomon incorporant un tel circuit |
| US5684794A (en) | 1996-01-25 | 1997-11-04 | Hazeltine Corporation | Validation of subscriber signals in a cellular radio network |
| GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| JP2002514196A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジノンおよびピリドン化合物ならびに使用方法 |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| JP2001522844A (ja) * | 1997-11-06 | 2001-11-20 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ピリミジノン化合物およびそれを含有する医薬組成物 |
| EP1105377B1 (fr) | 1998-08-21 | 2003-10-08 | SmithKline Beecham plc | Derives de pyrimidinone destines au traitement de l'atherosclerose |
| DE60042286D1 (de) | 1999-05-01 | 2009-07-09 | Smithkline Beecham Plc | Pyrimidinon Verbindungen |
| GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
-
2000
- 2000-10-10 GB GBGB0024808.8A patent/GB0024808D0/en not_active Ceased
-
2001
- 2001-10-05 EP EP01978400A patent/EP1326841B1/fr not_active Expired - Lifetime
- 2001-10-05 CZ CZ2003-1009A patent/CZ304558B6/cs not_active IP Right Cessation
- 2001-10-05 ES ES10177773T patent/ES2399325T3/es not_active Expired - Lifetime
- 2001-10-05 ES ES01978400T patent/ES2378059T3/es not_active Expired - Lifetime
- 2001-10-05 AU AU1052402A patent/AU1052402A/xx active Pending
- 2001-10-05 NZ NZ525225A patent/NZ525225A/en not_active IP Right Cessation
- 2001-10-05 IL IL15527801A patent/IL155278A0/xx unknown
- 2001-10-05 KR KR1020037005084A patent/KR100824134B1/ko active IP Right Grant
- 2001-10-05 CN CNB018201253A patent/CN1280275C/zh not_active Expired - Fee Related
- 2001-10-05 SI SI200131008T patent/SI1326841T1/sl unknown
- 2001-10-05 SI SI200131019T patent/SI2258688T1/sl unknown
- 2001-10-05 WO PCT/EP2001/011610 patent/WO2002030904A1/fr active IP Right Grant
- 2001-10-05 HU HU0302480A patent/HU230767B1/hu not_active IP Right Cessation
- 2001-10-05 MX MXPA03003176A patent/MXPA03003176A/es active IP Right Grant
- 2001-10-05 BR BRPI0114576A patent/BRPI0114576B1/pt not_active IP Right Cessation
- 2001-10-05 PT PT01978400T patent/PT1326841E/pt unknown
- 2001-10-05 EP EP10177773A patent/EP2258688B1/fr not_active Expired - Lifetime
- 2001-10-05 PT PT101777738T patent/PT2258688E/pt unknown
- 2001-10-05 AU AU2002210524A patent/AU2002210524B2/en not_active Ceased
- 2001-10-05 CN CN200610128890XA patent/CN1951917B/zh not_active Expired - Fee Related
- 2001-10-05 JP JP2002534290A patent/JP4212354B2/ja not_active Expired - Fee Related
- 2001-10-05 CA CA2425268A patent/CA2425268C/fr not_active Expired - Fee Related
- 2001-10-05 DK DK01978400.8T patent/DK1326841T3/da active
- 2001-10-05 AT AT01978400T patent/ATE538096T1/de active
- 2001-10-05 PL PL366334A patent/PL207560B1/pl unknown
- 2001-10-05 US US10/399,022 patent/US20040063753A1/en not_active Abandoned
- 2001-10-05 DK DK10177773.8T patent/DK2258688T3/da active
- 2001-10-08 TW TW090124779A patent/TWI293293B/zh not_active IP Right Cessation
- 2001-10-08 MY MYPI20014669A patent/MY135766A/en unknown
- 2001-10-08 GC GCP20011661 patent/GC0000307A/en active
- 2001-10-10 AR ARP010104760A patent/AR035349A1/es active IP Right Grant
-
2003
- 2003-04-08 IL IL155278A patent/IL155278A/en not_active IP Right Cessation
- 2003-04-09 NO NO20031626A patent/NO325107B1/no not_active IP Right Cessation
- 2003-04-09 ZA ZA200302785A patent/ZA200302785B/en unknown
- 2003-12-08 HK HK10111562.3A patent/HK1144941A1/xx not_active IP Right Cessation
- 2003-12-08 HK HK03108904.5A patent/HK1058036A1/xx not_active IP Right Cessation
-
2004
- 2004-07-28 US US10/900,489 patent/US7235566B2/en not_active Expired - Lifetime
-
2012
- 2012-03-07 CY CY20121100228T patent/CY1112442T1/el unknown
-
2013
- 2013-02-08 CY CY20131100118T patent/CY1113648T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL155278A0 (en) | Pyridinone derivatives for treatment of atherosclerosis | |
| IL213240A0 (en) | Method of treatment using lighnd-immunogen conjugates | |
| GB0014969D0 (en) | Novel method of treatment | |
| AU2001286983A1 (en) | Method of treatment | |
| AU7845701A (en) | Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals | |
| IL152810A0 (en) | Novel polymorph v of torasemide | |
| HUP0300703A3 (en) | Process for the preparation of quinoline derivatives | |
| GB2380481B (en) | Means for treatment of atherosclerosis | |
| GB0008921D0 (en) | Method of treatment | |
| HUP0301027A3 (en) | Process for the extraction of 2-hydroxy pyridine 2-hydroxyquinoline and 2-hydroxybenzothiazole derivatives | |
| EP1359912A4 (fr) | Nouvelles methodes utilisant des derives de pyridine | |
| EP1303281A4 (fr) | Methodes de traitement | |
| PL343942A1 (en) | Novel derivative of isothiazole pyridine | |
| AU6789501A (en) | Method of dusting-preventive treatment of powder having dusting property | |
| GB0002762D0 (en) | Method of treatment | |
| PL340617A1 (en) | Derivatives of 2-acylpyridine | |
| PL341634A1 (en) | Method of obtaining derivatives of phenylsulphonylmethyltetrazole | |
| GB0026742D0 (en) | Novel method of treatment | |
| AUPQ662500A0 (en) | Method of treatment | |
| AUPR213000A0 (en) | Method of treatment | |
| AUPQ949500A0 (en) | Method of treatment | |
| GB0013928D0 (en) | Methods of treatment | |
| GB0014904D0 (en) | Methods of treatment | |
| AUPQ811200A0 (en) | Treatment of alopecia | |
| GB0023674D0 (en) | Method of lowering product cost |